Director of CMC Policy and Advocacy
GlaxoSmithKline
Riley Myers is Director of CMC Policy and Advocacy at GlaxoSmithKline. Prior to joining GSK, Dr. Myers was Director of Technical Operations at the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and spent 11 years at the U.S. Food and Drug Administration (FDA), serving in multiple scientific and leadership roles. He was the founding Chief of the Advanced Manufacturing Research Facility within CDER’s Office of Pharmaceutical Quality and a member of the Emerging Technology Team. He was also a founding member of the Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) working group, where he contributed to the development of approaches for regulating future advanced manufacturing technologies. Dr. Myers also served as a Lead Biologist in the Office of Biotechnology Products, leading teams responsible for quality assessments. Before joining FDA, Dr. Myers studied mechanisms to program anti-pathogenic immune responses at Boston Children’s Hospital. He earned his Ph.D. in Immunology from the University of Alabama at Birmingham.
